How to get your corporate R&D to operate like a startup

Too much bureaucracy often leaves corporate R&D departments hamstrung.

It’s little wonder that biotechs were responsible for 38 of the 59 new therapies approved in 2018 compared with 21 for the big pharmaceutical companies, according to Biotechnology Innovation Organization research cited in a recent Harvard Business Review article.

The authors of the HBR article were Harvard Medical School professor Jeff Karp, who leads a biomedical research laboratory, and Ken Banta, who  served as a senior executive in several large global biopharma companies and now runs a C-suite consultancy. Go to HBR and read their advice on how big companies can make their R&D groups more effective.